To conclude, in order to evaluate whether dual blockade promotes changes to biomarkers associated with immunomodulation, a phase II study is being performed on HER2+ advanced BC patients treated with at least 2 prior lines of anti-HER2-targeted therapies. This evidence concerns the gene ERBB2 and breast cancer.